AstraZeneca raised its earnings guidance for the full year, after its margins were boosted by soaring sales of higher priced oncology and rare disease drugs and a drop in revenue from non-profit contracts for its Covid-19 vaccine.
阿斯利康(AstraZeneca)上調了全年營收指引，此前，由于該公司價格較高的腫瘤和罕見病藥物銷量飆升，以及新冠疫苗的非盈利合同收入下降，其利潤率得到提高。
您已閱讀17%（310字），剩余83%（1553字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。